Format

Send to

Choose Destination
Am J Geriatr Psychiatry. 2010 Oct;18(10):928-39. doi: 10.1097/JGP.0b013e3181d5792a.

Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy.

Author information

1
Bangor University, United Kingdom. l.clare@bangor.ac.uk

Abstract

OBJECTIVES:

To provide evidence regarding the clinical efficacy of cognitive rehabilitation (CR) in early-stage Alzheimer disease (AD).

DESIGN:

Single-blind randomized controlled trial comparing CR with relaxation therapy and no treatment.

SETTING:

Outpatient, community-based setting.

PARTICIPANTS:

Sixty-nine individuals (41 women, 28 men; mean age 77.78 years, standard deviation 6.32, range = 56-89) with a diagnosis of AD or mixed AD and vascular dementia and a Mini-Mental State Examination score of 18 or above, and receiving a stable dose of acetylcholinesterase-inhibiting medication. Forty-four family carers also contributed.

INTERVENTION:

Eight weekly individual sessions of CR consisting of personalized interventions to address individually relevant goals supported by components addressing practical aids and strategies, techniques for learning new information, practice in maintaining attention and concentration, and techniques for stress management.

MEASUREMENTS:

The primary outcomes were goal performance and satisfaction, assessed using the Canadian Occupational Performance Measure. Questionnaires assessing mood, quality of life and career strain, and a brief neuropsychological test battery were also administered. A subset of participants underwent functional magnetic resonance imaging (fMRI).

RESULTS:

CR produced significant improvement in ratings of goal performance and satisfaction, whereas scores in the other two groups did not change. Behavioral changes in the CR group were supported by fMRI data for a subset of participants.

CONCLUSIONS:

The findings support the clinical efficacy of CR in early-stage AD. CR offers a means of assisting people with early-stage AD and their families in managing the effects of the condition.

PMID:
20808145
DOI:
10.1097/JGP.0b013e3181d5792a
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center